



### Supplementary figure 1

**Validation of detected miRNAs in an independent sample cohort.** Levels of miR-145 and miR-150 are significantly different between MS and non-inflammatory neurological disease controls (NINDC). Relative levels of mature miRNAs were measured in validation set 2 (n=142) using multiplexed specific TaqMan miRNA assays and normalized to spike-in (ath-miR159a) (let-7e, n=58; let-7g, n=139; miR-21, n=118; miR-30a, n=139; miR-31, n=20; miR-133a, n=99; miR-142-3p, n=122; miR-145, n=138; miR-146a, n=120; miR-150, n=138; miR-193a-3p, n=121; miR-193b, n=88; miR-203, n=82; miR-204, n=140; miR-886-3p, n=88). Lines represent median and interquartile range. \*p<0.05, \*\*p<0.01.